In a different phase II trial, pyrotinib was administered as either first or subsequent line in patients with advanced HER2-mutant NSCLC, yielding an ORR of 19.2% and a median PFS of 5.6 months. Here, ERBB2 is linked to non-small cell lung carcinoma.